Capital News

CD BioSciences Introduces Full-service Clinical Pharmacology Supports to Early Phase Programs

 Breaking News
  • No posts were found

CD BioSciences Introduces Full-service Clinical Pharmacology Supports to Early Phase Programs

September 12
17:54 2020
With years of exploration and expansion, CD BioSciences now unveils its full-service clinical pharmacology studies to evaluate drug safety, tolerance and pharmacokinetics, delivering unique insights for go/no-go decisions.

New York, USA – September 12, 2020 – As the first and critical step in evaluating the novel drugs, early phase clinical trials lay the groundwork for the later phase clinical trials that are yet to come. Clinical pharmacology is the study of drugs in humans. In the early 1900s, scientists began to combine the study of physiological effects with biological effects, which led to the first major breakthrough of discovering insulin. Now, clinical pharmacology has expanded to be a multidisciplinary field and has contributed to the understanding of drug interaction, therapeutic efficacy and safety in humans.

CD BioSciences is fully capable to conduct clinical trials in healthy volunteers, patients, and special populations to fit specific drug development programs. The patient database capabilities cover a variety of therapeutic areas, including cardiovascular disease, infectious disease, oncology disease, etc. Experts at CD BioSciences are also highly experienced in a wide range of clinical pharmacology studies, including but not limited to:

• First-in-human single ascending dose and multiple ascending dose (SAD and MAD)
• Dose proportionality
• Drug-drug interaction (DDI)
• Adaptive protocol design
• Cardiac safety including definitive QTc/thorough QT (TQT)
• Clinical pharmacokinetics/pharmacodynamics (PK/PD)

In addition, CD BioSciences are skillful in handling specialty clinical pharmacology procedures, such as serial and continuous cerebrospinal fluid (CSF) collection, inhalation/intranasal delivery, intratympanic injection, drug-alcohol interaction, etc.

With cutting-edge facilities and a team of scientists with extensive experience in clinical pharmacology studies, CD BioSciences has already delivered dozens of cases of integrated clinical trials with biologics and small molecules, and is looking forward to working with more partners to advance their projects.

“To assist the clinical pharmacology studies as well as the whole process of early phase clinical trials, we also provide clinical data management services including data collection, extraction, data processing, coding, analysis and other management services, which will ensure reliable, accurate, top-quality data to our worldwide clients.” Introduced by a senior scientist at CD BioSciences.

As a world-leading service provider in the field of clinical trial development, CD BioSciences is dedicated to providing expert CRO services for every stage of your clinical trial. Detailed information about the services and case studies can be found on https://www.cd-biosciences.com.

About CD BioSciences

Founded in 2004, and located in New York, CD BioSciences offer a full range of clinical trial consulting, design, conduction, management, reporting and analysis services to advance clinical trial development needs of global clients. The clinical trial services focus on the entire clinical trial lifecycle including bioanalytical lab testing, clinical pharmacology, first-in-human (FIH), proof of concept (POC), early phase trials, CDM analysis and reporting, and biostatistics services.

Media Contact
Company Name: CD BioSciences
Contact Person: Michelle Moser
Email: Send Email
Phone: 1-631-619-7922
Country: United States
Website: https://www.cd-biosciences.com

Categories